| Rheumatoid Arthritis
Olumiant vs Kevzara
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Olumiant vs Kevzara with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKevzara has a higher rate of injection site reactions vs Olumiant based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kevzara but not Olumiant, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Olumiant
Kevzara
At A Glance
Oral
Once daily
JAK inhibitor
SC injection
Every 2 weeks
IL-6 receptor antagonist
Indications
- Rheumatoid Arthritis
- COVID-19 Virus Disease
- Alopecia Areata
- Rheumatoid Arthritis
- Polymyalgia Rheumatica
- Juvenile polyarthritis
Dosing
Rheumatoid Arthritis 2 mg once daily orally, with or without food; may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.
COVID-19 Virus Disease 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first.
Alopecia Areata 2 mg once daily orally; increase to 4 mg once daily if response is not adequate; reduce back to 2 mg once daily when adequate response is achieved.
Rheumatoid Arthritis 200 mg SC injection once every 2 weeks; may be used as monotherapy or in combination with methotrexate or other conventional DMARDs.
Polymyalgia Rheumatica 200 mg SC injection once every 2 weeks in combination with a tapering course of corticosteroids; may be used as monotherapy following discontinuation of corticosteroids.
Juvenile polyarthritis 200 mg SC injection once every 2 weeks for patients weighing 63 kg or greater; may be used as monotherapy or in combination with conventional DMARDs.
Contraindications
—
- Known hypersensitivity to sarilumab or any of the inactive ingredients
Adverse Reactions
Most common (>=1%) Upper respiratory tract infections, nausea, herpes simplex, herpes zoster, acne, hyperlipidemia, urinary tract infections, headache, fatigue, folliculitis, lower respiratory tract infections, genital Candida infections, anemia, neutropenia, liver enzyme elevations, blood creatine phosphokinase increased, thrombocytosis, deep vein thrombosis, pulmonary embolism
Serious Serious infections, mortality, malignancy and lymphoproliferative disorders, major adverse cardiovascular events, thrombosis, hypersensitivity, gastrointestinal perforations, laboratory abnormalities
Postmarketing Drug hypersensitivity including rash, urticaria, and angioedema
Most common (>=3%) Neutropenia, increased ALT, injection site erythema, upper respiratory tract infections, urinary tract infections
Serious Serious infections (pneumonia, cellulitis), gastrointestinal perforation, hypersensitivity reactions, neutropenia, thrombocytopenia, elevated liver enzymes, lipid abnormalities
Pharmacology
Baricitinib is a JAK inhibitor that selectively inhibits JAK1, JAK2, and TYK2, preventing phosphorylation and activation of STATs and thereby modulating cytokine signaling pathways involved in hematopoiesis and immune cell function.
IL-6 receptor antagonist; sarilumab is a human recombinant IgG1 monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), inhibiting IL-6-mediated pro-inflammatory signaling involved in T-cell activation, acute phase protein synthesis, and joint inflammation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Olumiant
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
Kevzara
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Olumiant
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Kevzara
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (2/8)
Humana
Olumiant
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Kevzara
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Olumiant Savings Card - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Rheumatoid Arthritis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OlumiantView full Olumiant profile
KevzaraView full Kevzara profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.